Results 181 to 190 of about 3,969,245 (300)

Flavivirus Nonstructural Protein 1‑Driven Coagulation via Tissue Factor-Bearing Microvesicles: A Pilot Study. [PDF]

ACS Omega
Beltrami S, Ferraresi M, Cianci G, Narducci M, Rizzo R, Baroni M, Bortolotti D.   +6 more
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Soluble tissue factor generated by necroptosis-triggered shedding is responsible for thrombosis. [PDF]

Cell Res
Wan P, Choksi S, Park YJ, Chen X, Yan J, Foroutannejad S, Liu Z, Chen J, Lake R, Liu C, Liu ZG.   +10 more
europepmc   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Tissue Factor Expression in Penile Squamous Cell Carcinoma: A Potential Marker of HPV-Independent Disease. [PDF]

Cancers (Basel)
Jackson JC, Johns AC, Campos Clemente L, Manuel CM, Qiao W, Lu W, Khan K, Solis Soto LM, Chahoud J, Rao P, Campbell MT, Pettaway CA, Zacharias NM.   +12 more
europepmc   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Tissue factor activity and 1-year mortality in patients with active cancer and acute ischemic stroke: findings from the SCAN study. [PDF]

Res Pract Thromb Haemost
Gon Y, Kawano T, Kitano T, Yamagami H, Abe S, Hashimoto H, Ohara N, Takahashi D, Abe Y, Takahashi T, Takasugi J, Kanki H, Sasaki T, Sakaguchi M.   +13 more
europepmc   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Tissue Factor [PDF]

Science-Business eXchange, 2011
  +4 more sources

The efficacy of rosuvastatin to reduce circulating tissue factor extracellular vesicles after ovarian cancer surgery. [PDF]

Blood Adv
Osataphan S, Patell R, Babuta M, Rosovsky RP, Hisada Y, Edmiston C, Elavalakanar P, Pfeffer MA, Bregar A, Ramos A, Garrett L, Ren S, Neuberg D, Szabo G, Flaumenhaft R, Mackman N, Shea M, Zwicker JI.   +17 more
europepmc   +1 more source